Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

NCT01048892 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01048892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01048892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2009
Completion date
Not reported
Enrollment
22 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma, gastrointestinal carcinoid tumor, kidney cancer, neuroblastoma, retinoblastoma, sarcoma